Boston Scientific has completed the $435m purchase of Switzerland-based firm Symetis, under the definitive agreement signed by the companies in March.
The transaction expands Boston Scientific’s structural heart portfolio and enhances its treatment options for patients suffering from valvular heart disease.
Symetis focuses on the development of minimally invasive transcatheter aortic valve implantation (TAVI) devices, and will now be integrated into the interventional cardiology division of Boston Scientific.
With the acquisition now complete, Boston Scientific plans to immediately commence the sale of Symetis’ ACURATE TA and ACURATE neo/TF valve systems in markets outside the US.
Boston Scientific executive vice-president and global chief medical officer Ian Meredith said: "Adding the ACURATE family of valve products to our structural heart portfolio presents us with the opportunity to provide two distinctly different but complementary TAVI platforms.
"Enabling implanting physicians and hospitals to treat the broadest range of patients and aortic valve anatomies, this valve offering, along with our left atrial appendage closure device, uniquely positions us to advance structural heart solutions for patients, while fueling continued growth for the company."
Similar to Boston Scientific’s LOTUS valve system, the ACURATE valves are being developed for the treatment of severe and symptomatic aortic valve stenosis patients, who have a high risk of surgical valve replacement.
Boston Scientific intends to continue the development of the next-generation ACURATE neo/AS valve system, which is currently under evaluation in a clinical trial being conducted to support a future CE mark application.